Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing

Abstract

Identification of regulators of osteoblastogenesis that can be pharmacologically targeted is a major goal in combating osteoporosis, a common disease of the elderly population. Here, unbiased kinome RNAi screening in primary murine osteoblasts identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation in both murine and human preosteoblastic cells. Cdk5 knockdown by siRNA, genetic deletion using the Cre-loxP system, or inhibition with the small molecule roscovitine enhanced osteoblastogenesis in vitro. Roscovitine treatment significantly enhanced bone mass by increasing osteoblastogenesis and improved fracture healing in mice. Mechanistically, downregulation of Cdk5 expression increased Erk phosphorylation, resulting in enhanced osteoblast-specific gene expression. Notably, simultaneous Cdk5 and Erk depletion abrogated the osteoblastogenesis conferred by Cdk5 depletion alone, suggesting that Cdk5 regulates osteoblast differentiation through MAPK pathway modulation. We conclude that Cdk5 is a potential therapeutic target to treat osteoporosis and improve fracture healing.

References

[1] Bianco P, Robey PG. Skeletal stem cells. Development, 2015, 142: 1023-1027

[2] Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS. Biology of bone tissue: structure, function, and factors that influence bone cells. BioMed. Res. Int., 2015, 2015: 421746

[3] Feng X, McDonald JM. Disorders of bone remodeling. Annu. Rev. Pathol., 2011, 6: 121-145

[4] Binkley N. Osteoporosis in men. Arq. Brasi. Endocrinol. Metab., 2006, 50: 764-774

[5] Russow, G. et al. Anabolic therapies in osteoporosis and bone regeneration. Int. J. Mol. Sci. 20, 83 (2018).

[6] Neer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344: 1434-1441

[7] Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas, 2014, 78: 199-204

[8] Kornak U, Mundlos S. Genetic disorders of the skeleton: a developmental approach. Am. J. Hum. Genet., 2003, 73: 447-474

[9] Geister KA, Camper SA. Advances in skeletal dysplasia genetics. Annu. Rev. Genom. Hum. Genet., 2015, 16: 199-227

[10] Wagner EF, Karsenty G. Genetic control of skeletal development. Curr/. Opin. Genet. Dev., 2001, 11: 527-532

[11] Ahmad M et al. Cell-based RNAi screening and high-content analysis in primary calvarian osteoblasts applied to identification of osteoblast differentiation regulators. Sci. Rep., 2018, 8

[12] Carles, F., Bourg, S., Meyer, C. & Bonnet, P. PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials. Molecules 23, 908 (2018).

[13] Hellmich MR, Pant HC, Wada E, Battey JF. Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc. Natl. Acad. Sci. USA, 1992, 89: 10867-10871

[14] Shetty KT, Link WT, Pant HC. cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. Proc. Natl. Acad. Sci. USA, 1993, 90: 6844-6848

[15] Chang KH, Vincent F, Shah K. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J. Cell. Sci., 2012, 125: 5124-5137

[16] Tang D et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem., 1995, 270: 26897-26903

[17] Lew J et al. A brain-specific activator of cyclin-dependent kinase 5. Nature, 1994, 371: 423-426

[18] Ohshima T et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. USA, 1996, 93: 11173-11178

[19] Shah K, Lahiri DK. Cdk5 activity in the brain—multiple paths of regulation. J. Cell. Sci., 2014, 127: 2391-2400

[20] Eurexpress. Eurexpress: A transcriptome atlas database for mouse embryo. <http://www.eurexpress.org/ee/> (2008).

[21] Diez-Roux G et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol., 2011, 9: e1000582

[22] Filgueira de Azevedo W Jr., Gaspar RT, Canduri F, Camera JC Jr., Freitas da Silveira NJ. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun., 2002, 297: 1154-1158

[23] Röntgen V et al. Fracture healing in mice under controlled rigid and flexible conditions using an adjustable external fixator. J. Orthop. Res., 2010, 28: 1456-1462

[24] Matsushita T et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell Biol., 2009, 29: 5843-5857

[25] Banks AS et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature, 2015, 517: 391-395

[26] Chae T et al. Mice lacking p35, a neuronal-specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron, 1997, 18: 29-42

[27] Humbert S, Dhavan R, Tsai L. p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J. Cell. Sci., 2000, 113: 975-983

[28] Tomizawa K, Cai XH, Moriwaki A, Matsushita M, Matsui H. Involvement of cyclin-dependent kinase 5/p35(nck5a) in the synaptic reorganization of rat hippocampus during kindling progression. Jpn. J. Physiol., 2000, 50: 525-532

[29] Tomizawa K et al. Localization and developmental changes in the neuron-specific cyclin-dependent kinase 5 activator (p35nck5a) in the rat brain. Neuroscience, 1996, 74: 519-529

[30] Wilkaniec A, Czapski GA, Adamczyk A. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J. Neurochem., 2016, 136: 222-233

[31] Nguyen MD, Julien JP. Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis. Neuro-Signals, 2003, 12: 215-220 74623

[32] Paoletti P et al. Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci., 2008, 28: 10090-10101

[33] Lopes JP, Oliveira CR, Agostinho P. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer’s disease and prion-related encephalopathies. Cell. Mol. Neurobiol., 2007, 27: 943-957

[34] Li BS et al. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem., 2003, 278: 35702-35709

[35] Modi PK, Komaravelli N, Singh N, Sharma P. Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol. Biol. Cell, 2012, 23: 3722-3730

[36] Lenjisa JL et al. CDK5 in oncology: recent advances and future prospects. Fut. Med. Chem., 2017, 9: 1939-1962

[37] Pozo K, Bibb JA. The emerging role of Cdk5 in cancer. Trends Cancer, 2016, 2: 606-618

[38] Merk H et al. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis. Oncotarget, 2016, 7: 6088-6104

[39] Lampropoulou E et al. Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration. Sci. Rep., 2018, 8

[40] Zhuang K et al. CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis. Cell Death Dis, 2016, 7

[41] Cicenas J et al. Roscovitine in cancer and other diseases. Ann. Transl. Med., 2015, 3: 135

[42] Kino T et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol. Endocrinol., 2007, 21: 1552-1568

[43] Pfänder P, Fidan M, Burret U, Lipinski L, Vettorazzi S. Cdk5 deletion enhances the anti-inflammatory potential of GC-mediated GR activation during inflammation. Front. Immunol., 2019, 10: 1554

[44] Pfänder P, Eiers AK, Burret U, Vettorazzi S. Deletion of Cdk5 in macrophages ameliorates anti-inflammatory response during endotoxemia through induction of C-Maf and Il-10. Int. J. Mol., 2021, 22: 9648

[45] Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 2013, 140: 3079-3093

[46] Malumbres M. Cyclin-dependent kinases. Genome Biol., 2014, 15

[47] Takahashi A et al. Loss of cyclin-dependent kinase 1 impairs bone formation, but does not affect the bone-anabolic effects of parathyroid hormone. J. Biol. Chem., 2018, 293: 19387-19399

[48] Saito M et al. The indispensable role of cyclin-dependent kinase 1 in skeletal development. Sci. Rep., 2016, 6

[49] Gemini-Piperni S et al. Kinome profiling of osteoblasts on hydroxyapatite opens new avenues on biomaterial cell signaling. Biotechnol. Bioeng., 2014, 111: 1900-1905

[50] Zou W et al. The microtubule-associated protein DCAMKL1 regulates osteoblast function via repression of Runx2. J. Exp. Med., 2013, 210: 1793-1806

[51] Kim JH et al. Kruppel-like factor 4 attenuates osteoblast formation, function, and cross talk with osteoclasts. J. Cell Biol., 2014, 204: 1063-1074

[52] Kulkarni NH et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J. Bone Miner. Res., 2006, 21: 910-920

[53] Gilmour PS et al. Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats. Toxicol. Appl. Pharmacol., 2013, 272: 399-407

[54] Kim JW et al. Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration. Eur. J. Pharmacol., 2017, 806: 10-17

[55] Mohammad KS et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One, 2009, 4: e5275

[56] Meijer L et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem./FEBS, 1997, 243: 527-536

[57] Akiba Y et al. The inhibitors of cyclin-dependent kinases and GSK-3beta enhance osteoclastogenesis. Biochem. Biophys. Rep., 2016, 5: 253-258

[58] Loiselle AE, Lloyd SA, Paul EM, Lewis GS, Donahue HJ. Inhibition of GSK-3β rescues the impairments in bone formation and mechanical properties associated with fracture healing in osteoblast selective connexin 43 deficient mice. PLoS One, 2013, 8: e81399

[59] Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat. Rev. Rheumatol., 2012, 8: 133-143

[60] Haffner-Luntzer M. Experimental agents to improve fracture healing: utilizing the WNT signaling pathway. Injury, 2020, 52: S44-S48

[61] Marongiu G, Dolci A, Verona M, Capone A. The biology and treatment of acute long-bones diaphyseal fractures: overview of the current options for bone healing enhancement. Bone Rep., 2020, 12: 100249

[62] Choi YH, Gu YM, Oh JW, Lee KY. Osterix is regulated by Erk1/2 during osteoblast differentiation. Biochem. Biophys. Res. Commun., 2011, 415: 472-478

[63] Ge C et al. Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res., 2012, 27: 538-551

[64] Jiang L, Tang Z. Expression and regulation of the ERK1/2 and p38 MAPK signaling pathways in periodontal tissue remodeling of orthodontic tooth movement. Mol. Med. Rep., 2018, 17: 1499-1506

[65] Benson C et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer, 2007, 96: 29-37

[66] Le Tourneau C et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur. J. Cancer, 2010, 46: 3243-3250

[67] Shlomo Melmed. Treatment of Cushing’s disease with R-roscovitine, <https://clinicaltrials.gov/ct2/show/NCT02160730> (2018).

[68] Liebl J et al. Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. Nat. Commun., 2015, 6: 7274

[69] Liu P et al. Dicer ablation in osteoblasts by Runx2 driven cre-loxP recombination affects bone integrity, but not glucocorticoid-induced suppression of bone formation. Sci. Rep., 2016, 6

[70] Morgan EF et al. Micro-computed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone, 2009, 44: 335-344

[71] Rapp AE et al. Induced global deletion of glucocorticoid receptor impairs fracture healing. FASEB J., 2018, 32: 2235-2245

[72] Parfitt AM et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res., 1987, 2: 595-610

[73] Amling M et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology, 1999, 140: 4982-4987

[74] Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am. J. Physiol. Endocrinol. Metab., 2006, 290: E456-E462

[75] Marini F, Binder H. pcaExplorer: an R/Bioconductor package for interacting with RNA-seq principal components. BMC Bioinform., 2019, 20

[76] Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun., 2019, 10

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation)(CRC1149 (INST 40/492-2))